Biblio

Author Title [ Type

] Year

Filters: Author is Kim, Won Seog [Clear All Filters]

Journal Article

Berning P, Schmitz N, Ngoya M, Finel H, Boumendil A, Wang F, Huang X-J, Hermine O, Philippe L, Couronné L, et al. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis. Leukemia. 2023.

Jeong SHyun, Song H-N, Park JSeong, Yang D-H, Koh Y, Yoon S-S, Lee HWon, Eom HSeok, Won J-H, Kim WSeog, et al. Allogeneic stem cell transplantation for patients with natural killer/T-cell lymphoid malignancy: a multicenter analysis comparing upfront and salvage transplantation. Biol Blood Marrow Transplant. 2018.

Park S, Kim K, Jang JHo, Kim SJin, Kim WSeog, Jung CWon. Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation. Oncotarget. 2016.

Kim KHa, Lee JHoon, Lee M, Kim H-G, Do YRok, Park Y, Oh SYong, Shin H-J, Kim WSeog, Park S-K, et al. Busulfan, Melphalan, and Etoposide (Bume) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High Risk Non-Hodgkin's Lymphoma: A Mul. Cancer Res Treat. 2022.

Kim SJin, Jo J-C, Yoon DHyun, Yang D-H, Yoon SEun, Lee G-W, Kong JHyun, Park Y, Kang K-W, Lee H-S, et al. Comparison of first-line treatment with CHOP versus ICED in patients with peripheral T-cell lymphoma eligible for upfront autologous stem cell transplantation. Front Oncol. 2023;13:1230629.

Cho H, Yoon DHyun, Shin D-Y, Koh Y, Yoon S-S, Kim SJin, Do YRok, Lee G-W, Kwak J-Y, Park Y, et al. Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404). Cancer Res Treat. 2023.

Ohmachi K, Niitsu N, Uchida T, Kim SJin, Ando K, Takahashi N, Takahashi N, Uike N, Eom HSeok, Chae YSoo, et al. Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2013.

Yi JHo, Jeong SHyun, Kim SJin, Yoon DHyun, Kang HJin, Koh Y, Kim JSeok, Lee W-S, Yang D-H, Do YRok, et al. Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. Cancer Res Treat. 2022.

Kim SJin, Yoon DHyun, Yang D-H, Eom HSeok, Cho SGoo, Yoon S-S, Lee JHoon, Kim WSeog, Suh C. Plerixafor use for peripheral blood stem cell mobilization in Korea. Blood Res. 2013;48(2):72-3.

Park S, Kim K, Jang JHo, Kim SJin, Kim WSeog, Chung DRyeon, Kang C-I, Peck KRan, Jung CWon. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. J Infect. 2016.

Jeon Y, Yoon SEun, Cho J, Kim SJin, Kim WSeog. Retrospective analysis of diagnosis and therapeutic strategies for patients with hepatosplenic T cell lymphoma. Ann Hematol. 2023.

Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas R-O, Ysebaert L, Damaj G, Guidez S, Pica GMatteo, Kim WSeog, et al. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol. 2021:JCO2101815.

Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas R-O, Ysebaert L, Damaj GLaurent, Guidez S, Pica GMatteo, Kim WSeog, et al. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial. J Clin Oncol. 2024:JCO2301687.

Kim KHa, Kim WSeog, Kim SJin, Yoon DHyun, Suh C, Kang HJin, Choi CWon, Lee HSup, Bae SHwa, Park J, et al. Treatment with Intravenous Busulfan, Melphalan, and Etoposide (BuME) followed by Autologous Stem Cell Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from the Consortium for Improving Survival of Lymphoma (CISL). Transpl Int. 2020.